Literature DB >> 1371898

Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.

H Joensuu1, K Kätkä, H Kujari.   

Abstract

The combination of alpha-interferon and octreotide has rarely been tested in the treatment of carcinoid syndrome. We describe a patient who was moribund when treated with interferon alone, but enjoyed a dramatic response leading to disappearance of all symptoms, normalization of dU-5-HIAA, and restoration of his normal life-style when octreotide was initiated. Neither interferon nor octreotide could be withdrawn without reappearance of the symptoms, suggesting that the combination of alpha-interferon and octreotide may have synergistic effects in carcinoid syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371898     DOI: 10.1530/acta.0.1260184

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  3 in total

Review 1.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

2.  Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Authors:  R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

3.  Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group.

Authors:  Keith Stuart; Donna E Levy; Tom Anderson; Constantine A Axiotis; Janice P Dutcher; Andrew Eisenberg; John K Erban; Al Bowen Benson III
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.